Sars Cov 2 Rna Fragments, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sars cov 2 rna fragments/product/ATCC
Average 94 stars, based on 4 article reviews
Price from $9.99 to $1999.99
1) Product Images from "Optical trapping assisted label-free and amplification-free detection of SARS-CoV-2 RNAs with an optofluidic nanopore sensor"
Article Title: Optical trapping assisted label-free and amplification-free detection of SARS-CoV-2 RNAs with an optofluidic nanopore sensor
Journal: Biosensors & Bioelectronics
Figure Legend Snippet: Flowchart of the magnetic-bead-based target extraction and preconcentration method. a, Magnetic carrier microbeads with 14 base pair long pulldown oligonucleotides. pd: pull-down sequence. b, SARS-CoV-2 negative human nasopharyngeal swab (NPS) solution and synthetic SARS-CoV-2 RNA solution is mixed with the magnetic carrier beads and processed using heating, magnetic pulldown, and washing steps to extract targets onto beads (details see main text). c, Target-functionalized magnetic carrier beads for detection on optofluidic nanopore chip.
Techniques Used: Sequencing, Chromatin Immunoprecipitation
Figure Legend Snippet: SARS-CoV-2 nanopore TACRE assay. a, Real-time translocations of SARS-CoV-2 RNAs from TACRE method and control experiment. The gray region in the TACRE trace represents the 150s heating period for target release. b, Number of translocations from SARS-CoV-2 RNAs in bulk solution at different concentrations within 360s detection time window. c, Detection of SARS-CoV-2 RNAs at different initial concentrations with TACRE method. (Circles: data; crosses: predicted number of events). d, Number of translocations (red solid circles) vs initial target concentration normalized to the case of 10 trapped beads and 20 RNAs/bead. Purple solid line: expected number of translocations in ( c ) after normalization, which is 200 for all the concentrations. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Techniques Used: Concentration Assay
Figure Legend Snippet: Optical trapping assisted nanopore capture rate enhancement (TACRE) platform. a, Optofluidic chip with connected solid-core (SC, gray) and liquid-core (LC, blue) waveguides. Reservoirs are attached over channel outlets and nanopore (NP) location. Voltages V EK and V NP are applied for electrokinetic delivery of bead-bound targets to the nanopore and translocation of released targets through nanopore, respectively. A light beam guided through the LC waveguide traps and collects carrier microbeads at the nanopore location. b, Closeup of TACRE process at NP location: targets are released from the beads while beads are trapped by the optical beam in the fluidic channel. Region (I): targets inside this region at the beginning of the experiment can diffuse to the nanopore capture volume within the duration of the experiment. Region (II): nanopore capture volume for particle translocations. c, SEM image of a terraced micro-well to create thin membrane for ion milling of 20 nm nanopore (inset). d, Baseline-corrected nanopore current for SARS-CoV-2 RNA segments translocating through the pore. Red dots mark individual RNA molecules identified by custom peak-finding algorithm. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Techniques Used: Chromatin Immunoprecipitation, Translocation Assay
2) Product Images from "Mitoxantrone modulates a heparan sulfate-spike complex to inhibit SARS-CoV-2 infection"
Article Title: Mitoxantrone modulates a heparan sulfate-spike complex to inhibit SARS-CoV-2 infection
Journal: Scientific Reports
Figure Legend Snippet: Mitoxantrone inhibits the entry of SARS-CoV-2 into a lung epithelial cell line. (A) Cells grown in monolayer were treated with Mitoxantrone (200 nM) and then infected with SARS-CoV-2 (USA-WA1/2020) at an MOI of 0.1. Five hours later, cells were fixed and stained with rabbit anti-spike antibodies in combination with goat anti-rabbit IgG conjugated with Alexa Fluor 488 (left panels). (B) Quantification of spike fluorescence intensity in (A) . ****, p
Techniques Used: Infection, Staining, Fluorescence
Figure Legend Snippet: Mitoxantrone inhibits SARS-CoV-2 infection in an EpiAirway 3D tissue model. (A) A schematic diagram of the experimental design. (B) Remdesivir (2 μM) but not Bleomycin (100 μM) inhibits SARS-CoV-2 infection. 24 or 96 h after drug treatment and viral infection (MOI 0.1), the cell surface was washed. The viral titer (TCID50) in the wash was determined. (C,D) Mitoxantrone inhibits SARS-CoV-2 infection in the EpiAirway 3D model. TCID50 was determined either 24 h (C) or 96 h (D) after the organoids were treated with the drug at the indicated concentrations and then air-infected with SARS-CoV-2 at MOI 0.1 for 1 h. The cells were washed from the apical side to remove the virus in the cell exterior and then incubated for 24 (C) or 96 h (D) . Cells were rinsed from the apical side again and viral titers in the wash were determined. The dashed lines indicate the viral titer from cells infected without Mitoxantrone or in the presence of 2 mM Remdesivir (Rem.), as indicated. (E) Bleomycin (100 μM) but not Remdesivir (2 μM) induces cell death, releasing LDH as determined by a luciferase assay. *, p
Techniques Used: Infection, Incubation, Luciferase